Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
MinION™ is a portable device for molecular analyses that was developed by Oxford Nanopore
MinION™ is a portable device for molecular analyses that was developed by Oxford Nanopore

A new partnership aims to build on Oxford’s impressive track record in creating spinout companies, creating many more businesses which will stand among the world’s leading science-based enterprises.

The University of Oxford and Isis Innovation, the University’s technology commercialisation subsidiary, have launched a partnership with newly created Oxford Sciences Innovation plc (OSI) to develop the University’s world-leading scientific research.

Read more

Similar stories

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

New Research Highlights Importance of Early Years Development on Future Wellbeing

Oxford researchers involved nearly 4,000 children across the UK in three specially developed science lessons to educate pupils about brain development during early childhood. The SEEN (Secondary Education around Early Neurodevelopment) project was commissioned and funded by KindredSquared and is part of a wider drive to increase public understanding of how early experiences can shape the adults we become.

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.